𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

✍ Scribed by Jetske M. Meerum Terwogt; Gerard Groenewegen; Dick Pluim; Marc Maliepaard; Matthijs M. Tibben; Albert Huisman; Wim W. ten Bokkel Huinink; Margaret Schot; Helen Welbank; Emile E. Voest; Jos H. Beijnen; Jan H. Schellens

Publisher
Springer
Year
2002
Tongue
English
Weight
166 KB
Volume
49
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase I and pharmacokinetic study of h
A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma
✍ Edward F. McClay; Mary-Eileen T. McClay; Jeffery A. Jones; Paul J. Winski; Rando πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 2 views

by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r

Phase I and pharmacokinetic study of a s
Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors : The relation between pharmacokinetic property and toxicity
✍ Ruey-Long Hong; Yun-Long Tseng πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 2 views

## BACKGROUND. Compared with free drug, sterically stabilized liposomal drug has prolonged circulation time and, thereby, higher tumor selectivity and antitumor activity. The stability in plasma is an important consideration in the formulation of clinically useful liposomal drug. A Phase I study o

Phase I and pharmacokinetic study of a l
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
✍ Francis J. Giles; Martin S. Tallman; Guillermo Garcia-Manero; Jorge E. Cortes; D πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 130 KB

## Abstract ## BACKGROUND OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has significant activity in severe combined immunodeficient mouse models of human leukemia. ## METHODS This study was conducted to define the dose